February 4, 2014 - Today Sandoz recognizes World Cancer Day. Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008, according to the World Health Organization. Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1 million deaths in 2030.
The high cost of treating cancer can be a significant barrier to patients. Well over half of all cancer deaths (70%) in 2008 occurred in low- and middle-income countries, according to the World Health Organization. Sandoz oncology injectables and biosimilars offer high-quality treatment alternatives for cancer patients at more affordable prices.
Sandoz’s contribution to fighting cancer
“Our vision is to improve patient access to high-quality oncology injectables and biosimilars by offering these critical products at a lower price than the originator medicine,” said Mark McCamish, Sandoz Global Head of Biopharmaceuticals and Oncology Injectables Development. “The greater affordability of biosimilars and oncology injectables may also result in clinical benefits through earlier and wider appropriate therapeutic use and the savings generated can also be used by healthcare systems to fund novel treatments.”
Oncology injectable medicines address the needs of traditional chemotherapy, the backbone of cancer treatment. They are a highly specialized class of product and are difficult to produce due to their toxic characteristics and need for special preparation and handling. Sandoz is one of a few companies with global development, manufacturing and commercial expertise in this challenging and growing sector, supported by a strong track record of development around complex patent landscapes. To deliver on its vision of global leadership, Sandoz concentrates on customers and their needs.
Biosimilars are approved biologics with similar safety, efficacy and quality to a reference product that has lost patent exclusivity. Biologics are often the only medicines capable of effectively treating complex diseases including various types of cancer and autoimmune disorders.
“Biologics are wonderful agents that provide significant benefits to patients. They have revolutionized the cancer treatment paradigm. With biologics, we can add life and function to patients living with cancer. They are also expensive, which affects their use and patient access. At Sandoz, we produce high-quality, more affordable biosimilars, when the originator patent expires,” said McCamish.